Potential treatment – Page 6 – Communicable Diseases Research

DrugWAS: Drug-wide Association Studies for COVID-19 Drug Repurposing

DrugWAS: COVID-19 약물 용도 변경에 대한 약물 전반의 협회 연구

Article

Published on 2021-12-012022-09-11
Journal: Clinical Pharmacology and Therapeutics [Category] MERS, 신약개발,

Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review

Review article

Published on 2021-12-012022-10-05
Journal: European journal of pharmacology [Category] SARS, 임상, 치료법,

Inhibiting ACSL1-Related Ferroptosis Restrains Murine Coronavirus Infection

Article

Published on 2021-11-282022-10-28
Journal: Viruses [Category] COVID-19, MERS,

[키워드] ACSL1 administration ameliorated Apoptosis approach C57BL/6 caused Cell coronavirus Coronavirus infection expression Ferroptosis Genes Hepatitis Host hyper-inflammation in vivo indicate induce inducer infected cells Infection Inflammatory cytokine inhibited inhibitor intranasal involved Lung inflammation lytic cell death Macrophage macrophages MHV-A59 mice mouse hepatitis virus (MHV) murine necroptosis pathogenicity performed Potential treatment PROTECT pyroptosis released RNA-Seq shown suppressed Syncytia syncytia formation targeting therapy tissue injury TLR4 upregulate upregulation viral propagation virus strain
[DOI] 10.3390/v13122383 PMC 바로가기 [Article Type] Article

Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review

COVID-19의 잠재적 치료를위한 용도 기반 약리학 적제 : 문헌 검토

Review

Published on 2021-11-272022-08-31
Journal: Respiratory Research [Category] MERS, SARS, 신약개발, 치료제,

[키워드] “cytokine storm” affected analysed anticoagulation article articles Azithromycin benefit Chloroquine clinical benefit clinical benefits clinical trial clinical trials Clinical use Coagulopathy cohorts collected confirmation Corticosteroids Course COVID-19 COVID-19 pandemic COVID-19 patients COVID-19 pneumonia Cytokine storm death Dexamethasone disease Disease progression drug drug names Efficacy Efficacy and safety elicited examined Google Scholar Hydroxychloroquine IL-6 IL-6 receptor literature review Lopinavir Lopinavir/ritonavir mechanically ventilated mechanically ventilated COVID-19 patients monoclonal antibodies monoclonal antibody Mortality multiple organ failure Organ failure Other oxygen Oxygen therapy Pathogenesis pathophysiologic patients with COVID-19 pharmacological pharmacological agent pharmacological agents pharmacological treatment Pneumonia Potential treatment prevent disease progression professional Randomised controlled trials Randomised trial receptor antagonist Remdesivir Research Respiratory complications Result Ritonavir SARS-CoV-2 severe COVID-19 shown significantly Stage Supplemental oxygen therapy tested the disease Tocilizumab treat Treatment treatment of COVID-19 utilised were used
[DOI] 10.1186/s12931-021-01885-8 PMC 바로가기 [Article Type] Review

CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

촉매 시험 프로토콜 : 입원 성인의 COVID-19에 대한 잠재적 치료의 초기 및 가속 평가를위한 멀티 센터, 오픈 라벨, 2 단계, 다중 암 시험.

Intensive Care

Published on 2021-11-112022-09-10
Journal: BMJ Open [Category] Fulltext, MERS, SARS, 임상,

[키워드] accelerated Admission adult intensive & critical care Analysis approval approved Biomarker C reactive protein candidate drugs chest X-ray clinical clinical picture COVID-19 CRP CT scan death dissemination dysregulated immune response East Efficacy eligible Ethics ethics committee Evidence evidence of hospital discharge hospitalised Hospitalised patients identify immunomodulation IMPROVE improvement include Infectious diseases inflammatory monocyte inflammatory monocytes initial International Macrophage macrophages MHRA Monocytes multicentre National Open-label outcome Patient peer-reviewed platform Platform trial Pneumonia positive Potential treatment primary outcome measure proinflammatory protocol public health registration numbers Research Ethics reverse transcription PCR rheumatology SARS-COV-2 infection SARS-CoV-2 pneumonia scale secondary Secondary outcomes severe SARS the WHO therapeutic strategy thoracic medicine Treatment Trial trials usual care with COVID-19
[DOI] 10.1136/bmjopen-2021-050202 PMC 바로가기 [Article Type] Intensive Care

Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19

Clinical Trial

Published on 2021-11-012022-10-05
Journal: Clinical and translational science [Category] 임상,

Antiviral Activities of Andrographolide and Its Derivatives: Mechanism of Action and Delivery System

Review

Published on 2021-10-282022-10-28
Journal: Pharmaceuticals [Category] COVID-19,

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

COVID19의 잠재적인 치료를 위한 정맥 코로나바이러스 3CL 프로테아제 억제제의 전임상 특성화

Article

Published on 2021-10-182022-09-10
Journal: Nature Communications [Category] MERS, SARS, 변종, 신약개발, 치료제,

Pulmonary vascular system: A vulnerable target for COVID‐19

Review

Published on 2021-10-172022-10-30
Journal: MedComm [Category] COVID-19,

[키워드] acute respiratory syndrome binding caused change clinical presentation clinician coagulation cascade Coagulopathy Community coronavirus coronavirus disease COVID‐19 COVID‐19 direct infection Diseases dysfunction Effect endothelial Endothelial cell endothelial damage endotheliopathy entry receptor enzyme expressed global pandemic hallmark healthcare hosts immune dysregulation Infection Inflammation Intussusceptive angiogenesis occur oxidative stress pathologic pathophysiology Potential treatment pulmonary pulmonary vascular system recent reported SARS‐CoV‐2 SARS‐CoV‐2 infection SARS‐CoV‐2 significantly surface receptor susceptible the disease therapeutic strategy thrombosis Vascular vascular endothelial damage Vascular injury vasculature
[DOI] 10.1002/mco2.94 PMC 바로가기 [Article Type] Review

SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies

Review

Published on 2021-10-162022-10-04
Journal: International immunopharmacology [Category] MERS, SARS, 변종, 신약개발, 유전자 메커니즘,

[키워드] Abstract ACE-2, Angiotensin-converting enzyme 2 AKI, acute kidney injury Ang II, Angiotensin II BALF, Broncho alveolar lavage fluid cGMP, Good Manufacturing Practice Characteristics coronavirus disease 19 COVID-19 COVID-19 infection COVID-19, Coronavirus disease of 2019 CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats CRS, Cytokine release syndrome CT, Computed tomography CT, Cycle threshold current Cytokine storm DENV, dengue virus develop diagnostic tests dimension drugs emerging variants FDA, Food and Drug Administration FNR, False‐negative rate Genome GGOs, Ground-glass opacities global effort HAT, Human airway trypsin-like protease health emergency Health Organization HIV, Human immunodeficiency virus IBV, infectious bronchitis virus ICU, Intensive care unit IL, interleukin immune response immune responses Immunity include Infection International JEV, Japanese encephalitis virus lack LAMP, Loop-mediated isothermal amplification LF, Lactoferrin mechanism MIP1α, Macrophage inflammatory protein 1α MRI, Magnetic resonance imaging MSC, Mesenchymal Stem Cells Mutation mutations NCD, Newcastle disease virus new virus NP, nasopharyngeal NSPs, Nonstructural proteins OP, Oropharyngeal pandemic Pathogenesis pathogenicity Potential treatment Prevent problem RAS, Renin-angiotensin system RBD, Receptor binding-domain RdRp, RNA-dependent RNA polymerases Reinfection Research resulting SARS-CoV SARS-CoV-2 SARS-COV-2, severe acute respiratory syndrome coronavirus-2 severity TGF, Transforming growth factor Th17, T helper 17 the disease the SARS-CoV-2 therapeutic therapy Transmissibility treat Vaccine vaccine candidate Vaccine development Vaccines variant variants variants of SARS-CoV-2 virus VLPs, Virus-like particles VTM, Viral transport medium while WHO WNV, West Nile virus
[DOI] 10.1016/j.intimp.2021.108232 PMC 바로가기 [Article Type] Review